Neuropathic Pain Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033

The new report published by The Business Research Company, titled Neuropathic Pain Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the neuropathic pain market size has grown strongly in recent years. It will grow from $4.95 billion in 2023 to $5.35 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $7.16 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Rising Prevalence Of Chronic Pain Drives Growth In The Neuropathic Pain Market
The growing prevalence of chronic pain is expected to propel the growth of the neuropathic pain market going forward. Chronic pain is persistent and ongoing pain that lasts beyond the expected healing time of an injury or illness. It is characterized by its duration, typically lasting at least three to six months or more. The rising prevalence of chronic pain, including neuropathic conditions, requires effective treatments, spurring research, innovation and investment in improved therapies to enhance symptom relief and quality of life. For instance, in April 2023, according to the Morbidity and Mortality Weekly Report (MMWR) published by the Centers for Disease Control and Prevention, a US-based national public health agency, approximately 51.6 million U.S. adults (20.9%) dealt with chronic pain and 17.1 million (6.9%) experienced high-impact chronic pain in 2021. Further, the prevalence of chronic pain among U.S.-born individuals (21.6%) was almost twice that of those born outside the U.S. (11.9%). Similarly, high-impact chronic pain was more prevalent among U.S.-born individuals (7.0%) than those born outside the U.S. (4.1%). Therefore, the growing prevalence of chronic pain is driving the growth of the neuropathic pain market going forward.

Integration Of Artificial Intelligence Revolutionizes Neuropathic Pain Treatment
Major companies operating in the neuropathic pain market are adopting artificial intelligence technologies for advanced diagnosis, tailored treatment plans, real-time monitoring, drug discovery and data-driven insights to enhance patient outcomes and refine pain management strategies. For instance, in March 2023, Nevro Corp., a US-based medical device company, launched the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology employs artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger and HFX App, is designed to treat non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It uses a unique algorithm based on extensive patient data and allows patients to adjust their pain relief program via a smartphone app. The system's digital environment enables data collection and potential updates. The technology aims to enhance pain relief through consistency and personalization, marking a significant advance in SCS therapy.

The neuropathic pain market covered in this report is segmented -

1) By Treatment: Medications; Multimodal Therapy
2) By Diagnosis: Imaging; Blood Tests And Physical Examination
3) By Indication: Diabetic Neuropathy; Spinal Stenosis; Chemotherapy-Induced Peripheral Neuropathy; Other Indications
4) By End User: Hospitals; Clinics; Home Healthcare; Ambulatory Surgical Centers; Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12922&type=discount

Major players in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc. , Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc., B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes.

Contents of the report:
1. Executive Summary
2. Neuropathic Pain Market Report Structure
3. Neuropathic Pain Market Trends And Strategies
4. Neuropathic Pain Market - Macro Economic Scenario
5. Neuropathic Pain Market Size And Growth
…..
27. Neuropathic Pain Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.